Antibiogram

ANTIBIOGRAM
This document contains data obtained from January 1 through December 31, 2013 and is designed to assist the clinician in the selection of empiric antimicrobial therapy for initial infections. University Health - Shreveport
Whenever possible, only the first isolate of a given species from an individual patient has been included for analysis. The Clinical Antibiogram: January - December 2013
Microbiology Laboratory utilizes microdilution MIC testing as the primary method of susceptibility testing, and supplements, as needed, with other methods such as disk diffusion and the E-test. Interpretation of testing results – Susceptible (S), Intermediate (I), or Resistant (R) – is based on guidelines developed by the Clinical Laboratory Standards Institute (CLSI). Selection of antimicrobials to be tested is made in collaboration with the pediatric and adult Infectious Diseases faculties, the hospital Pharmacy Department, and the Antibiotic Review Committee. The Clinical Microbiology POSITIVE d
Laboratory can develop antibiograms for specific areas of the medical center (e.g., specific floors, special care units, individual clinics). Discuss your requests with Dr. Gerald Capraro, Director of Clinical Microbiology (ext. 5-4611), or with Michelle Dillard- Wayne, Manager of Clinical Microbiology (ext. 5-7846). Key Aspects of the Antibiogram:
• Data are presented as % Susceptible. • Out of a total of 592 In-Patient Staphylococcus aureus isolates, • Out of a total of 179 Out-Patient Staphylococcus aureus isolates, • For Staphylococcus species, susceptibility to oxacillin predicts susceptibility to most cephalosporins, carbapenems, and β- lactam/β-lactamase inhibitor combinations. Staphylococcus species demonstrating resistance to oxacillin are reported as resistant to all penicillins, cephalosporins, carbapenems, and β- lactam/β-lactamase inhibitor combinations. • Enterococcus species are always resistant to aminoglycosides (except high concentrations), cephalosporins, clindamycin, and 1 Total In-Patient and Out-Patient. Not identified to species level unless isolated from a normally sterile site.
• Out of a total of 673 Out-Patient Escherichia coli isolates, 80% 2 Rifampin should not be used as monotherapy due to the rapid development of resistance.
3 Staphylococcus species that are erythromycin-resistant & clindamycin-susceptible are tested for inducible clindamycin resistance prior to reporting.
• ESBL-producing organisms were observed in isolates of 4 Increasing resistance rate for clindamycin makes this antibiotic a less suitable second line agent for treatment of pneumococcal infections.
Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca. These isolates were rare in 2013. • Of the 63 Acinetobacter baumannii isolates in 2013, 49% were • Yeast: 45 Candida isolates in 2013: 56% C. albicans (96% Susceptible to Fluconazole) 44% non-albicans Candida (40% Susceptible to Fluconazole) University Health - Shreveport
Antibiogram: January - December 2013
NEGATIVE
gram 2013
88% of H . influenzae isolates were β-lactama se ne gative. Of the 12% that were β- lactamase- positive, all were susceptible to ceftriaxone and trimethoprim- sulfamethoxazole.

Source: http://myhsc.lsuhscshreveport.edu/uploads/public/documents/pharmacy/antibiogram/2013AntibiogramBrochure.pdf